Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsBusinessMoneycontrol ResearchZydus Lifesciences: Why we are getting constructive

    Zydus Lifesciences: Why we are getting constructive

    There is a steady progress in product approvals and clinical trials for Zydus' niche products meant for rare ailments

    Anubhav Sahu
    November 08, 2023 / 10:44 IST
    On the biosimilar front, while Zydus is focused on consolidating its domestic business of 13 products, it is also investing in trials for new products
    • PRO Panorama

      Moneycontrol Pro Panorama | A new AI order is reshaping real estate 

      Nov 21, 2025 / 03:34 PM IST

      Moneycontrol's Pro Panorama November 21 edition: CAG audit reveals problems in Delhi's broken bus services, India’s private bank...

      Read Now
    • PRO Weekender

      Moneycontrol Pro Weekender | Samvat 2082: The Will to Rise

      Oct 18, 2025 / 10:00 AM IST

      After a turbulent Samvat 2081, the markets step into the new year not with fireworks but with quiet resolve and the will to rise

      Read Now
    Unlock This Article

    Are you a PRO subscriber? Sign In

    What Do You Get

    • Ad free Experience

      Seamless navigation, faster responses.

    • Expert Perspective

      Explore 230+ exclusive editorials every month

    • +

      Uncover Insights from World-Renowned Experts and Journalists

    • Actionable Insights

      40+ weekly investment ideas + 3 to 4 daily technical calls

    • Virtual Events

      Exclusive Live Webinars for Expert Trading & Investment Strategies!

    • Newsletters

      Stay ahead with daily and weekly insights

    View Offers

    Unlock exclusive discounts

    Disclosure & Disclaimer

    This Research Report / Research Recommendation has been published by Moneycontrol Dot Com India Limited (hereinafter referred to as “MCD”) which is a registered Investment Advisor under the Securities and Exchange Board of India (Investment Advisers) ...Read More